GT BIOPHARMA, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
GT BIOPHARMA, INC. (GTBP) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $4.69 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-08-14
- 2026-06-30: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $4.69.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $4.69 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |